News

Miriam Isola, PhD, talks to us about the use of phone apps for COVID-19 contact tracing.

The new kit will have association with multiple certified labs for diagnostics, and will come at no profit for the maker company.

In all trial participants to date, the vaccine candidate led to seroconversion with binding antibody levels either at or above levels seen in convalescent sera.

Armand Balboni, MD, PHD, CEO of Appili Therapeutics, discusses work with favipiravir on a new front for the drug — the global search for COVID-19 treatment and prevention therapies.

A risk score that predicts critical illness in patients hospitalized with COVID-19 could help inform allocation of clinical resources.

Patient stratification, demographic representations, and plasma collection could aid the pursuit for an efficacious prophylaxis.

Study explores the antiviral mechanisms of C19orf66, an interferon-induced inhibitor.

New cases came to the attention of public health officials within Shulan on May 7.

Here is a look at infectious disease-related FDA news from the week of May 10, 2020.

We’ve compiled a list of noteworthy recall statements from this past week.

A summary of Contagion's top stories for May 15, 2020.

Elizabeth Leung, PharmD, shares SIDP's educational efforts surrounding COVID-19 treatment.

An antibody candidate from Sorrento has shown complete blockage of infection in early assessments. The company is now pursuing production and regulatory aid.

New research into a combination of antiviral therapies finds it is safe and appears to shorten disease course in patients with early coronavirus.

A new first-of-its-kind global registry aimed at sharing real-time information on hospital care and ICU admissions could expand the scope of SARS-CoV-2 research.

A briefing on the day's top stories.

In an in vitro reconstituted human respiratory epithelium model, the investigational drug inhibited replication of the novel coronavirus.

The first-of-its-kind, randomized, placebo-controlled, phase 1/2a trial will assess patients hospitalized at Florida and South Dakota institutions.

Some hepatitis C virus treatments for pediatric patients may be cost-effective.

New findings comparing cases since February to the last half-decade show the rate and severity of the rare inflammatory disease recently spiked in children.

Vaccine candidate mRNA-1273 has been granted Fast Track designation by the US FDA.

A summary of today's top stories.

Barriers to recommended vaccine coverage for low-income American adults include disparity in Medicaid programs and low reimbursement amounts, a new study found.

Efforts to speed diagnosis among men might help stem the spread of the disease.

Paul Sax, MD, discusses remdesivir, scientific literature in the age of COVID-19, and the pandemic's long-lasting effects on the future of health care.

A series of essays consider the privileges and ethics of an immunity-based "passport" to proceed with fewer restrictions in the age of COVID-19.

Treating severe COVID-19 patients with lopinavir-ritonavir did not have any significant effect compared to standard-care control patients.

A quick summary of the day's infectious disease headlines.

The agency provided 2 new recommendation guidelines for sponsors looking to assess potential preventive and therapeutic agents for the coronavirus.

What is the hopeful expectation of the new candidates, relative to previously developed vaccines?